Results of the SELECT Trial in Thyroid Cancer

Next-generation CAR T cells, including 1928T2Z and WZTL-002, continue to be investigated for the treatment of patients with large B-cell lymphoma.

Newer approaches for patients with relapsed/refractory multiple myeloma are moving away from chemoimmunotherapy and toward drugs with novel mechanisms of action.

An updated guideline and panel recommends treatment with sacituzumab govitecan for patients with HR-positive/HER2-negative metastatic breast cancer who are refractory to endocrine therapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Amrita Krishnan, MD, discussed with participants their choice of therapy for a patient with multiple myeloma who relapsed after receiving bortezomib, lenalidomide, and dexamethasone followed by autologous stem cell transplant and 2 years of lenalidomide maintenance.

During a Targeted Oncology™ Case-Based Roundtable™ event, Anna C. Pavlick, DO, MSc, MBA, BSN, discussed first-line therapy for a patient with metastatic melanoma.